Murine models of Alzheimer's disease and their use in developing immunotherapies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 10, 2010, Pages 847-859

  Wisniewski, Thomas ^a   Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Congophilic angiopathy; Immunization; Immunomodulation; Neurofibrillary tangles; Tau; Transgenic mice

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; MISSENSE MUTATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; TAUOPATHY; ANIMAL; DISEASE MODEL; MOUSE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE;

MURINAE; MUS MUSCULUS;

EID: 77956057086     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.05.004     Document Type: Review

References (237)

1. Rafii M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
2. Biran Y., Masters C.L., Barnham K.J., Bush A.I., Adlard P.A. Pharmacotherapeutic targets in Alzheimer's disease. J. Cell. Mol. Med. 2009, 13:61-86.
3. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative diseass. Annu. Rev. Neurosci. 2008, 31:175-193.
4. Wisniewski T., Konietzko U. Amyloid-β immunization for Alzheimer's disease. Lancet Neurol. 2008, 7:805-811.
5. Wisniewski T., Boutajangout A. Vaccination as a therapeutic approach for Alzheimer's disease. Mt. Sinai J. Med. 2010, 77:17-31.
6. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
7. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
8. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13.
9. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 1996, 3:16-32.
10. Gotz J., Chen F., van D.J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
11. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
12. King M.E., Kan H.M., Baas P.W., Erisir A., Glabe C.G., Bloom G.S. tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J. Cell Biol. 2006, 175:541-546.
13. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., Lee J.M. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging 1996, 17:893-901.
14. Sigurdsson E.M., Lee J.M., Dong X.W., Hejna M.J., Lorens S.A. Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol. Aging 1997, 18:591-608.
15. Frautschy S.A., Baird A., Cole G.M. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:8362-8366.
16. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature 1999, 400:173-177.
17. Sigurdsson E.M., Scholtzova H., Mehta P., Frangione B., Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol. 2001, 159:439-447.
18. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
19. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., Westaway D. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
20. Sigurdsson E.M., Knudsen E.L., Asuni A., Sage D., Goni F., Quartermain D., Frangione B., Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J. Neurosci. 2004, 24:6277-6282.
21. Asuni A., Boutajangout A., Scholtzova H., Knudsen E., Li Y., Quartermain D., Frangione B., Wisniewski T., Sigurdsson E.M. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur. J. Neurosci. 2006, 24:2530-2542.
22. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., LaFerla F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 2006, 281:1599-1604.
23. Blurton-Jones M., LaFerla F.M. Pathways by which Abeta facilitates tau pathology. Curr. Alzheimer Res. 2006, 3:437-448.
24. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236.
25. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
26. Eisele Y.S., Bolmont T., Heikenwalder M., Langer F., Jacobson L.H., Yan Z.X., Roth K., Aguzzi A., Staufenbiel M., Walker L.C., Jucker M. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12926-12931.
27. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
28. Cummings B.J., Pike C.J., Shankle R., Cotman C.W. beta-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 1996, 17:921-933.
29. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008.
30. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.L., Vigouret J.M., Paganetti P., Walsh D.M., Mathews P.M., Ghiso J., Staufenbiel M., Walker L.C., Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
31. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A.R. Long term effects of Aβ42 immunization in Alzheimer's disease: immune response, plaque removal and clinical function. Lancet 2008, 372:216-223.
32. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
33. Castellani R.J., Lee H.G., Zhu X., Perry G., Smith M.A. Alzheimer disease pathology as a host response. J. Neuropathol. Exp. Neurol. 2008, 67:523-531.
34. Shioi J., Georgakopoulos A., Mehta P., Kouchi Z., Litterst C.M., Baki L., Robakis N.K. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. J. Neurochem. 2007, 101:674-681.
35. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagoplan S., Johnson-Wood K., Kan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995, 373:523-527.
36. Masliah E., Sisk A., Mallory M., Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J. Neuropathol. Exp. Neurol. 2001, 60:357-368.
37. Hsiao K.K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
38. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
39. Fryer J.D., Taylor J.W., DeMattos R.B., Bales K.R., Paul S.M., Parsadanian M., Holtzman D.M. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 2003, 23:7889-7896.
40. Sw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropath. Exp. Neurol. 1997, 56:965-973.
41. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 1998, 152:307-317.
42. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286:2352-2355.
43. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 1998, 152:871-877.
44. Smith M.A., Hirai K., Hsiao K., Pappolla M., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 1998, 70:2212-2215.
45. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., Diamond D.M. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 2001, 891:42-53.
46. Tagliavini F., Prelli F., Ghiso J., Bugiani O., Serban D., Prusiner S.B., Farlow M.R., Ghetti B., Frangione B. Amyloid protein of Gerstmann-Straussler-Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N- terminal glycine at codon 58. EMBO J. 1991, 10:513-519.
47. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
48. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. U. S. A. 1997, 94:13287-13292.
49. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
50. Rockenstein E., Mallory M., Mante M., Sisk A., Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J. Neurosci. Res. 2001, 66:573-582.
51. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., Godaux E., Cordell B., Van L.F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 1999, 274:6483-6492.
52. Kumar-Singh S., Dewachter I., Moechars D., Lubke U., De J.C., Ceuterick C., Checler F., Naidu A., Cordell B., Cras P., Van B.C., Van L.F. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol. Dis. 2000, 7:9-22.
53. Brouwers N., Sleegers K., Van B.C. Molecular genetics of Alzheimer's disease: an update. Ann. Med. 2008, 40:562-583.
54. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
55. Citron M., Westaway D., Xia W.M., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., Hyslop P.S., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3:67-72.
56. Wolfe M.S. gamma-Secretase in biology and medicine. Semin. Cell Dev. Biol. 2009, 20:219-224.
57. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-Tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
58. Borchelt D.R., Ratovitski T., Van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
59. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Saad W.K., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
60. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
61. McGowan E., Eriksen J., Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22:281-289.
62. Wilhelmus M.M., de Waal R.M., Verbeek M.M. Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease. Mol. Neurobiol. 2007, 35:203-216.
63. Wisniewski T., Sadowski M. Preventing Aβ fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors. BMC Neurosci. 2008, 9:1-5.
64. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., Jansen K., Delucia M., Lin W.L., Dolios G., Wang R., Eckman C.B., Dickson D.W., Hutton M., Hardy J., Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
65. Vidal R., Frangione B., Rostagno A., Mead S., Revesz T., Plant G., Ghiso J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999, 399:776-781.
66. Vidal R., Revesz T., Rostagno A., Kim E., Holton J.L., Bek T., Bojsen-Moller M., Braendgaard H., Plant G., Ghiso J., Frangione B. A decamer duplication in the 3β region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:4920-4925.
67. Prelli F., Castaño E.M., Glenner G.G., Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 1988, 51:648-651.
68. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
69. Mahley R.W., Huang Y. Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. Ann. Neurol. 2009, 65:623-625.
70. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 1992, 135:235-238.
71. Wisniewski T., Golabek A.A., Matsubara E., Ghiso J., Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Commun. 1993, 192:359-365.
72. Wisniewski T., Ghiso J., Frangione B. Alzheimer's disease and soluble Aβ. Neurobiol. Aging 1994, 15:143-152.
73. Sadowski M., Pankiewicz J., Scholtzova H., Mehta P., Prelli F., Quartermain D., Wisniewski T. Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice. Proc. Natl Acad. Sci. U.S.A. 2006, 103:18787-18792.
74. Bales K.R., Verina T., Dodel R.C., Du Y.S., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo P., Ghetti B., Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997, 17:263-264.
75. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U. S. A. 1999, 96:15233-15238.
76. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., Paul S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 1999, 103:R15-R21.
77. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K.R., Hsiao Ashe K., Irizarry M.C., Hyman B.T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 2000, 47:739-747.
78. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 2005, 25:2803-2810.
79. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 2009, 29:6771-6779.
80. Reiman E.M., Caselli R.J., Yun L.S., Chen K.W., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the β4 allele for apolipoprotein E. N. Eng. J. Med. 1996, 334:752-758.
81. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:284-289.
82. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6820-6825.
83. Kok E., Haikonen S., Luoto T., Huhtala H., Goebeler S., Haapasalo H., Karhunen P.J. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 2009, 65:650-657.
84. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapyβ. Nat. Rev. Neurol 2010, 6:108-119.
85. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
86. Takeuchi A., Irizarry M.C., Duff K., Saido T., Hsiao Ashe K., Hasegawa H., Mann D.M., Hyman B.T., Iwatsubo T. Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 2000, 157:331-339.
87. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature 1998, 396:755-756.
88. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der K.N., Vingtdeux V., van de S.E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am.J.Pathol. 2004, 165:1289-1300.
89. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van E.L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
90. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
91. Dziewczapolski G., Glogowski C.M., Masliah E., Heinemann S.F. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2009, 29:8805-8815.
92. Spires T.L., Meyer-Luehmann M., Stern E.A., McLean P.J., Skoch J., Nguyen P.T., Bacskai B.J., Hyman B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy7. J. Neurosci. 2005, 25:7278-7287.
93. Tsai J., Grutzendler J., Duff K., Gan W.B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 2004, 7:1181-1183.
94. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
95. Colton C.A., Vitek M.P., Wink D.A., Xu Q., Cantillana V., Previti M.L., van Nostrand W.E., Weinberg J.B., Dawson H. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12867-12872.
96. Wilcock D.M., Gharkholonarehe N., van Nostrand W.E., Davis J., Vitek M.P., Colton C.A. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J. Neurosci. 2009, 29:7957-7965.
97. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 2002, 109:813-836.
98. Zhang-Nunes S.X., Maat-Schieman M.L., Van Duinen S.G., Roos R.A., Frosch M.P., Greenberg S.M. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006, 16:30-39.
99. Pfeifer L.A., White L.R., Ross G.W., Petrovitch H., Launer L.J. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurol. 2002, 58:1629-1634.
100. Domnitz S.B., Robbins E.M., Hoang A.W., Garcia-Alloza M., Hyman B.T., Rebeck G.W., Greenberg S.M., Bacskai B.J., Frosch M.P. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2005, 64:588-594.
101. Davis J., Xu F., Deane R., Romanov G., Previti M.L., Zeigler K., Zlokovic B.V., van Nostrand W.E. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 2004, 279:20296-20306.
102. Davis J., Xu F., Miao J., Previti M.L., Romanov G., Ziegler K., van Nostrand W.E. Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice. Neurobiol. Aging 2006, 27:946-954.
103. Xu F., Grande A.M., Robinson J.K., Previti M.L., Vasek M., Davis J., van Nostrand W.E. Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 2007, 146:98-107.
104. Levy E., Carman M.D., Fernandez-Madrid I., Lieberburg I., Power M.D., vanDuinen S.G., Bots G.Th.A.M., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248:1124-1126.
105. Grabowski T.J., Cho H.S., Vonsattel J.P., Rebeck G.W., Greenberg S.M. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 2001, 49:697-705.
106. Kumar-Singh S. Hereditary and sporadic forms of Abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. Int. J Mol. Sci. 2009, 10:1872-1895.
107. Attems J., Jellinger K.A. Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology-a pilot study. Acta Neuropathol. (Berl) 2004, 107:83-90.
108. Wilcock D.M., Vitek M.P., Colton C.A. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. Neuroscience 2009, 159:1055-1069.
109. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol. Neurodegener. 2009, 4:13.
110. Iqbal K., Liu F., Gong C.X., Alonso A.C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009, 118:53-69.
111. Zilka N., Korenova M., Novak M. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Acta Neuropathol. 2009, 118:71-86.
112. Gotz J., Barmettler R., Ferrari A., Goedert M., Probst A., Nitsch R.M. In vivo analysis of wild-type and FTDP-17 tau transgenic mice. Ann. NY Acad. Sci. 2000, 920:126-133.
113. Gotz J., Chen F., Barmettler R., Nitsch R.M. tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 2001, 276:529-534.
114. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
115. Lewis J., Dickson D., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
116. Ishihara T., Zhang B., Higuchi K., Yoshiyama Y., Trojanowski J.Q., Lee V.M. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 2001, 158:555-562.
117. Tanemura K., Akagi T., Murayama M., Kikuchi N., Murayama O., Hashikawa T., Yoshiike Y., Park J.M., Matsuda K., Nakao S., Sun X., Sato S., Yamaguchi H., Takashima A. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol. Dis. 2001, 8:1036-1045.
118. Egashira N., Iwasaki K., Takashima A., Watanabe T., Kawabe H., Matsuda T., Mishima K., Chidori S., Nishimura R., Fujiwara M. Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. Brain Res. 2005, 1059:7-12.
119. Lee V.M., Kenyon T.K., Trojanowski J.Q. Transgenic animal models of tauopathies. Biochim. Biophys. Acta 2005, 1739:251-259.
120. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
121. Murakami T., Paitel E., Kawarabayashi T., Ikeda M., Chishti M.A., Janus C., Matsubara E., Sasaki A., Kawarai T., Phinney A.L., Harigaya Y., Horne P., Egashira N., Mishima K., Hanna A., Yang J., Iwasaki K., Takahashi M., Fujiwara M., Ishiguro K., Bergeron C., Carlson G.A., Abe K., Westaway D., St George-Hyslop P., Shoji M. Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. Am. J Pathol 2006, 169:1365-1375.
122. Rosenmann H., Grigoriadis N., Eldar-Levy H., Avital A., Rozenstein L., Touloumi O., Behar L., Ben-Hur T., Avraham Y., Berry E., Segal M., Ginzburg I., Abramsky O. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 2008, 212:71-84.
123. Schindowski K., Bretteville A., Leroy K., Begard S., Brion J.P., Hamdane M., Buee L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006, 169:599-616.
124. Leroy K., Bretteville A., Schindowski K., Gilissen E., Authelet M., De D.R., Yilmaz Z., Buee L., Brion J.P. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol. 2007, 171:976-992.
125. Taniguchi T., Doe N., Matsuyama S., Kitamura Y., Mori H., Saito N., Tanaka C. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett. 2005, 579:5704-5712.
126. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
127. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
128. Mastrangelo M.A., Bowers W.J. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci. 2008, 9:81.
129. Andorfer C., Kress Y., Espinoza M., de S.R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003, 86:582-590.
130. Andorfer C., Acker C.M., Kress Y., Hof P.R., Duff K., Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 2005, 25:5446-5454.
131. Polydoro M., Acker C.M., Duff K., Castillo P.E., Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 2009, 29:10741-10749.
132. Boutajangout A., Frangione B., Brion J.P., Wisniewski T., Sigurdsson E.M. Presenilin 1 mutation promotes tau phosphorylation and aggregation in a novel Alzheimer's disease mouse model. Alz. Dementia 2008, 4:T185.
133. Boutajangout A., Frangione B., Wisniewski T., Brion J.P., Sigurdsson E.M. Influence of presenilin mutation on tau pathology in novel Alzheimer's disease mouse model. Alz Dementia 2009, 5:P445-P446.
134. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl Acad. Sci. U. S. A. 1997, 94:4109-4112.
135. Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Curr. Opin. Investig. Drugs 2007, 8:519-524.
136. Frenkel D., Dewachter I., Van L.F., Solomon B. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 2003, 21:1060-1065.
137. Lavie V., Becker M., Cohen-Kupiec R., Yacoby I., Koppel R., Wedenig M., Hutter-Paier B., Solomon B. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J. Mol. Neurosci. 2004, 24:105-114.
138. Schiltz J.G., Salzer U., Mohajeri M.H., Franke D., Heinrich J., Pavlovic J., Wollmer M.A., Nitsch R.M., Moelling K. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J. Mol. Med. 2004, 82:706-714.
139. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nat. Med. 2000, 6:916-919.
140. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U. S. A. 2001, 98:8850-8855.
141. Lemere C.A., Maron R., Selkoe D.J., Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 2001, 20:705-711.
142. Sigurdsson E.M., Scholtzova H., Mehta P., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol. 2001, 159:439-447.
143. Sigurdsson E.M., Frangione B., Wisniewski T. Immunization for Alzheimer's disease. Drug Dev. Res. 2002, 56:135-142.
144. Wisniewski T., Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathol. 2005, 15:72-77.
145. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurol 2005, 64:94-101.
146. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., Black R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 2008, 5:194-196.
147. Wisniewski T. Practice point commentary on, "Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial". Nat. Clin. Pract. Neurol. 2005, 1:84-85.
148. Boche D., Nicoll J.A. The role of the immune system in clearance of Aβ from the brain. Brain Pathol. 2008, 18:267-278.
149. Bombois S., Maurage C.A., Gompel M., Deramecourt V., Kowiak-Cordoliani M.A., Black R.S., Lavielle R., Delacourte A., Pasquier F. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol. 2007, 64:583-587.
150. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
151. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurol. 2005, 64:129-131.
152. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2005, 9:448-452.
153. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., Vlachouli C., Wilkinson D., Bayer A., Games D., Seubert P., Schenk D., Holmes C. Abeta species removal after Abeta42 immunization. J. Neuropathol. Exp. Neurol. 2006, 65:1040-1048.
154. Boche D., Zotova E., Weller R.O., Love S., Neal J.W., Pickering R.M., Wilkinson D., Holmes C., Nicoll J.A. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310.
155. Serrano-Pozo A., William C.M., Ferrer I., Uro-Coste E., Delisle M.B., Maurage C.A., Hock C., Nitsch R.M., Masliah E., Growdon J.H., Frosch M.P., Hyman B.T. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010, 133:1312-1327.
156. Sadowski M., Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Curr. Pharm. Des. 2007, 13:1943-1954.
157. Hock C., Konietzko U., Straffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Axel Wollmar M., Umbricht D., de Quervain D.J.F., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
158. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Boada Rovira M., Forette F., Orgogozo J.M. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial. Neurol 2005, 64:1553-1562.
159. Hock C., Konietzko U., Paspassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., Davey G., Moritz E., Nitsch R.M. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 2002, 8:1270-1276.
160. 2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.
161. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., Lemere C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 2006, 26:4717-4728.
162. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., Cribbs D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 2005, 174:1580-1586.
163. Zamora E., Handisurya A., Shafti-Keramat S., Borchelt D., Rudow G., Conant K., Cox C., Troncoso J.C., Kirnbauer R. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J. Immunol. 2006, 177:2662-2670.
164. Chackerian B., Rangel M., Hunter Z., Peabody D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006, 24:6321-6331.
165. Jennings G.T., Bachmann M.F. The coming of age of virus-like particle vaccines. Biol. Chem. 2008, 389:521-536.
166. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., Head E., Biragyn A., Cribbs D.H., Agadjanyan M.G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS. ONE. 2008, 3:e2124.
167. Head E., Pop V., Vasilevko V., Hill M., Saing T., Sarsoza F., Nistor M., Christie L.A., Milton S., Glabe C., Barrett E., Cribbs D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci. 2008, 28:3555-3566.
168. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Issazadeh S., Hancock W.W., Selkoe D. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 2000, 48:567-579.
169. Lemere C.A., Spooner E.T., Leverone J.F., Mori C., Clements J.D. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002, 23:991-1000.
170. Hara H., Monsonego A., Yuasa K., Adachi Y., Xiao X., Takeda S., Takahashi K., Weiner H.L., Tabira T. Development of a safe oral Ab vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alz. Dis. 2004, 6:483-488.
171. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., Lemere C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 2006, 1.
172. Nikolic W.V., Bai Y., Obregon D., Hou H., Mori T., Zeng J., Ehrhart J., Shytle R.D., Giunta B., Morgan D., Town T., Tan J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc. Natl. Acad. Sci. U. S. A 2007, 104:2507-2512.
173. Boutajangout A., Goni F., Knudsen E., Schreiber F., Asuni A., Quartermain D., Frangione B., Chabalgoity A., Wisniewski T., Sigurdsson E.M. Lack of cognitive impairment and reduced Aβ burden in Tg2576 mice following acute prophylactic oral immunization with an Aβ derivative. J. Alz. Dis. 2009, 18:961-972.
174. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
175. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
176. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., Golde T.E. Anti-Aβ42 and anti-Aβ40 specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest 2006, 116:193-201.
177. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002, 298:1379.
178. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunization against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
179. Racke M.M., Boone L.I., Hepburn D.L., Parsadanian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 2005, 25:629-636.
180. Wilcock D.M., Jantzen P.T., Li Q., Morgan D., Gordon M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 2007, 144:950-960.
181. Petrushina I., Ghochikyan A., Mkrtichyan M., Mamikonyan G., Movsesyan N., Ajdari R., Vasilevko V., Karapetyan A., Lees A., Agadjanyan M.G., Cribbs D.H. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation. 2008, 5:42.
182. Vermeer S.E., den H.T., Koudstaal P.J., Oudkerk M., Hofman A., Breteler M.M. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003, 34:392-396.
183. Kramer J.H., Reed B.R., Mungas D., Weiner M.W., Chui H.C. Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg. Psychiatry 2002, 72:217-220.
184. Sigurdsson E.M. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers. Dis. 2008, 15:157-168.
185. Noble W., Garwood C.J., Hanger D.P. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion. 2009, 3.
186. Kayed R., Jackson G.R. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr. Opin. Immunol. 2009, 21:359-363.
187. Sigurdsson E.M. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr. Alzheimer Res. 2009, 6:446-450.
188. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4051-4055.
189. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
190. Utton M.A., Noble W.J., Hill J.E., Anderton B.H., Hanger D.P. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J. Cell. Sci. 2005, 118:4645-4654.
191. Magnani E., Fan J., Gasparini L., Golding M., Williams M., Schiavo G., Goedert M., Amos L.A., Spillantini M.G. Interaction of tau protein with the dynactin complex. EMBO J. 2007, 26:4546-4554.
192. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Watanabe A., Titani K., Ihara Y. Hyperphosphorylation of tau in PHF. Neurobiol. Aging 1995, 16:365-371.
193. Sergeant N., David J.P., Lefranc D., Vermersch P., Wattez A., Delacourte A. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett. 1997, 412:578-582.
194. Butner K.A., Kirschner M.W. tau protein binds to microtubules through a flexible array of distributed weak sites. J. Cell Biol. 1991, 115:717-730.
195. Brion J.P., Flament-Durand J., Dustin P. Alzheimer's disease and tau proteins. Lancet 1986, 2:1098.
196. Brion J.P. Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease. J. Alzheimers Dis. 2006, 9:177-185.
197. Wang J.Z., Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol. 2008, 85:148-175.
198. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
199. Sergeant N., Bretteville A., Hamdane M., Caillet-Boudin M.L., Grognet P., Bombois S., Blum D., Delacourte A., Pasquier F., Vanmechelen E., Schraen-Maschke S., Buee L. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 2008, 5:207-224.
200. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 1993, 336:417-424.
201. Hamdane M., Sambo A.V., Delobel P., Begard S., Violleau A., Delacourte A., Bertrand P., Benavides J., Buee L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J. Biol. Chem. 2003, 278:34026-34034.
202. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Murphy M.P., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
203. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27:9115-9129.
204. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
205. Tampellini D., Magrane J., Takahashi R.H., Li F., Lin M.T., Almeida C.G., Gouras G.K. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem. 2007, 282:18895-18906.
206. Frost B., Jacks R.L., Diamond M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284:12845-12852.
207. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
208. Ren P.H., Lauckner J.E., Kachirskaia I., Heuser J.E., Melki R., Kopito R.R. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 2009, 11:219-225.
209. Aguzzi A. Cell biology: beyond the prion principle. Nature 2009, 459:924-925.
210. Sadowski M., Verma A., Wisniewski T. Infectious disease of the nervous system: prion diseases. Neurology in Clinical Practice 2008, 1567-1581. Elsevier, Philadelphia. W.G. Bradley, R.B. Daroff, G.M. Fenichel, J. Jankovic (Eds.).
211. Wisniewski T., Golabek A.A., Kida E., Wisniewski K.E., Frangione B. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 1995, 147:238-244.
212. Bolmont T., Clavaguera F., Meyer-Luehmann M., Herzig M.C., Radde R., Staufenbiel M., Lewis J., Hutton M., Tolnay M., Jucker M. Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP × Tau transgenic mice. Am. J. Pathol. 2007, 171:2012-2020.
213. Frackowiak J., Wisniewski H.M., Wegiel J., Merz G.S., Iqbal K., Wang K.C. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 1992, 84:225-233.
214. Jucker M., Heppner F.L. Cerebral and peripheral amyloid phagocytes-an old liaison with a new twist. Neuron 2008, 59:8-10.
215. Butovsky O., Kunis G., Koronyo-Hamaoui M., Schwartz M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci. 2007, 26:413-416.
216. El K.J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
217. Scholtzova H., Kascsak R.J., Bates K.A., Boutajangout A., Kerr D.J., Meeker H.C., Mehta P.D., Spinner D.S., Wisniewski T. Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J. Neurosci. 2009, 29:1846-1854.
218. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
219. Obregon D., Hou H., Bai Y., Nikolic W.V., Mori T., Luo D., Zeng J., Ehrhart J., Fernandez F., Morgan D., Giunta B., Town T., Tan J. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol. Dis. 2008, 29:336-353.
220. Town T., Laouar Y., Pittenger C., Mori T., Szekely C.A., Tan J., Duman R.S., Flavell R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008, 14:681-687.
221. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283:29639-29643.
222. Klybin I., Betts V., Blennow K., Zetterberg H., Wallin A., Lemere C.A., Cullen W.K., Welzel A., Peng Y., Wisniewski T., Selkoe D.J., Anwyl R., Walsh D.M., Rowan M.J. Aβ dimer-containing human cerebrospinal fluid disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 2008, 28:4231-4237.
223. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281:4292-4299.
224. Moretto N., Bolchi A., Rivetti C., Imbimbo B.P., Villetti G., Pietrini V., Polonelli L., Del S.S., Smith K.M., Ferrante R.J., Ottonello S. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J. Biol. Chem. 2007, 282:11436-11445.
225. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C.G., Cribbs D.H., Agadjanyan M.G. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 2007, 282:22376-22386.
226. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y., Bigio E.H., Shaw P., De Felice F.G., Krafft G.A., Klein W.L. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 2007, 100:23-35.
227. Lambert M.P., Velasco P.T., Viola K.L., Klein W.L. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol. Disord. Drug Targets 2009, 8:65-81.
228. Maji S.K., Perrin M.H., Sawaya M.R., Jessberger S., Vadodaria K., Rissman R.A., Singru P.S., Nilsson K.P., Simon R., Schubert D., Eisenberg D., Rivier J., Sawchenko P., Vale W., Riek R. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 2009, 325:328-332.
229. Puzzo D., Privitera L., Leznik E., Fa M., Staniszewski A., Palmeri A., Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 2008, 28:14537-14545.
230. Giuffrida M.L., Caraci F., Pignataro B., Cataldo S., De B.P., Bruno V., Molinaro G., Pappalardo G., Messina A., Palmigiano A., Garozzo D., Nicoletti F., Rizzarelli E., Copani A. beta-Amyloid monomers are neuroprotective. J. Neurosci. 2009, 29:10582-10587.
231. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
232. Wisniewski T., Prelli F., Scholtzova H., Chung E., Mehta P.D., Kascsak R., Kascsak R., Goni F. Immunotherapy targeting abnormal protein conformation. Alz. Dementia 2009, 5:P113.
233. Sigurdsson E.M., Quartermain D., Boutajangout A. Tau immunotherapy prevents cognitive decline and clears pathological tau in a mouse model. Alz Dementia 2008, 4:T191-T192.
234. Wisniewski T., Sigurdsson E.M. Therapeutic approaches for prion and Alzheimer's diseases. FEBS J. 2007, 274:3784-3798.
235. Goni F., Prelli F., Schreiber F., Scholtzova H., Chung E., Kascsak R., Brown D.R., Sigurdsson E.M., Chabalgoity J.A., Wisniewski T. High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. Neurosci. 2008, 153:679-686.
236. Tomiyama T., Matsuyama S., Iso H., Umeda T., Takuma H., Ohnishi K., Ishibashi K., Teraoka R., Sakama N., Yamashita T., Nishitsuji K., Ito K., Shimada H., Lambert M.P., Klein W.L., Mori H. A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 2010, 30:4845-4856.
237. Lee E.B., Leng L.Z., Lee V.M., Trojanowski J.Q. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 2005, 579:2564-2568.